

해외 바이오의약품 임상 현황 (2020.05.04~2020.05.10)

한국바이오의약품협회, 2020.5.12.
출처: ClinicalTrials.gov

○ 미국 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04363346	Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia	COVID-19	Drug: FT516	Masonic Cancer Center, University of Minnesota	Phase 1
NCT04349631	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19	COVID-19	Drug: HB-adMSCs	Hope Biosciences	Phase 2
NCT04323202	Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N	Basal Cell Carcinoma of the Head and Neck	Drug: Pembrolizumab Other: Tissue collection	Brian Gastman Case Comprehensive Cancer Center	Phase 1
NCT04285268	Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	Drug: Bortezomib Biological: Rituximab Drug: Venetoclax	Rutgers, The State University of New Jersey National Cancer Institute (NCI)	Phase 2
NCT04374565	Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia	Corona Virus Infection SARS-CoV 2 SARS Pneumonia Pneumonia	Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma	University of Virginia	Phase 2
NCT04344795	Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors	Solid Tumor Microsatellite-stable Colorectal Cancer (MSS CRC) Adenocarcinoma of the Lung Squamous Cell Carcinoma of Head and Neck Bladder Cancer Triple Negative Breast Cancer Gastric Cancer	Drug: TPST-1495 Drug: Pembrolizumab	Tempest Therapeutics	Phase 1
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04350463	A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers	Neoplasms	Drug: CC-90011 Drug: Nivolumab	Celgene	Phase 2

○ 중국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04368273	Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.	Cervical Cancer	Drug: PD-1 antibody	Peking University Third Hospital	Phase 1 Phase 2
NCT04299581	Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma	Hepatocellular Carcinoma	Drug: Camrelizumab Combination Product: US/CT-guided Percutaneous Cryoablation	Fudan University	Phase 2
NCT04297280	TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Sintilimab Combination Product: TACE	Fudan University	Phase 2

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04354480	A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older	Healthy	Biological: RSV Vaccine Other: Placebo	Janssen Pharmaceutical K.K.	Phase 1